Interpretation of WHO consolidated guidelines on tuberculosis Module 4: Treatment of drug-susceptible tuberculosis

doi:10.19982/j.issn.1000-6621.20220330

Chinese Journal of Antituberculosis ›› 2022, Vol. 44 ›› Issue (11): 1122-1125.doi: 10.19982/j.issn.1000-6621.20220330

• Interpretation of Standards • Previous Articles Next Articles

Interpretation of WHO consolidated guidelines on tuberculosis Module 4: Treatment of drug-susceptible tuberculosis

Yuan Yuan¹, Lu Shuihua²()

¹Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China
²National Clinical Research Center for Infectious Diseases/The Third People’s Hospital of Shenzhen/The Second Affiliated Hospital of Southern University of Science and Technology, Guangdong Province, Shenzhen 518112, China

Received:2022-08-29 Online:2022-11-10 Published:2022-11-03
Contact: Lu Shuihua E-mail:lushuihua66@126.com
Supported by:
Guangdong Clinical Research Center for Infectious Diseases (Tuberculosis)(2020B1111170014);Shenzhen Tuberculosis Clinical Medical Research Center (Shenzhen Science and Technology Innovation [2021]287)

Abstract

Abstract:

In 2010, World Health Organization (WHO) issued recommendations for the treatment of drug susceptible tuberculosis (DS-TB). This treatment regimen is widely used, but in clinical practice, it is found that many patients fail to complete the 6-month treatment due to the long treatment time. Based on two phase Ⅲ trials, for the first time, the 2022 WHO guidelines add to the evidence-based recommendations of the most recent 2021 guideline development panel, which recommended a 4-month regimen for DS-TB. In this article, the author interprets the treatment of DS-TB according to the latest 2022 guidelines.

Key words: Tuberculosis, pulmonary, Therapeutic uses, Consensus development conferences as topic

CLC Number:

R453
R521

Yuan Yuan, Lu Shuihua. Interpretation of WHO consolidated guidelines on tuberculosis Module 4: Treatment of drug-susceptible tuberculosis[J]. Chinese Journal of Antituberculosis, 2022, 44(11): 1122-1125. doi: 10.19982/j.issn.1000-6621.20220330

References 6

[1]	World Health Organization. Treatment of tuberculosis:guidelines for national programmes (4th Edition). Geneva: World Health Organization, 2010.
[2]	Dorman SE, Nahid P, Kurbatova EB, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med, 2021, 384(18): 1705-1718. doi: 10.1056/NEJMoa2033400. doi: 10.1056/NEJMoa2033400 URL
[3]	Chabala C, Turkova A, Thomason MJ, et al. Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. Trials, 2018, 19(1): 237. doi: 10.1186/s13063-018-2608-5. doi: 10.1186/s13063-018-2608-5 pmid: 29673395
[4]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: Treatment. Drug-susceptible tuberculosis treatment. Geneva: World Health Organization, 2022.
[5]	World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care. Geneva: World Health Organization, 2017.
[6]	贺晓新, 李波, 周林. 《4个月含利福喷丁抗结核治疗方案疗效观察》解读. 中国防痨杂志, 2021, 43(12):1243-1247. doi: 10.3969/j.issn.1000-6621.2021.12.004. doi: 10.3969/j.issn.1000-6621.2021.12.004

[1]	Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397.
[2]	Senior Department of Tuberculosis, the 8th Medical Center of Chinese PLA General Hospital , Editorial Board of Chinese Journal of Antituberculosis , Basic and Clinical Speciality Committees of Tuberculosis Control Branch of China International Exchange , Promotive Association for Medical and Health Care . Expert consensus on multidisciplinary diagnosis and treatment of tuberculous peritonitis [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 243-257.
[3]	Zhu Jiankun, Meng Qian, Kong Kangbao, Jin Feng. The value of pneumonectomy in the treatment of pulmonary mucormycosis [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 274-281.
[4]	He Zhongliang, Xu Weihua, Xin Shunxin, Chen Guoxing, He Xueming, Wang Lei. The application value of individualized precision treatment for closure of bronchopleural fistula after lung cancer resection surgery [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 282-286.
[5]	Expert Consensus on the Diagnosis and Treatment of Spinal Tuberculosis Combined with HIV/AIDS Patients Group, Combined with HIV/AIDS Patients Group Chinese Antituberculosis Association, Chinese Antituberculosis Association of STD and AIDS Prevention and Control, the Western China Bone Tuberculosis Alliance, the North China Bone the North China Bone. Expert consensus on diagnosis and treatment of spinal tuberculosis with HIV/AIDS (2nd Edition) [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 1-11.
[6]	Li Yang, Sun Feng, Zhang Wenhong. Short-course treatment for tuberculosis: past achievements and future directions [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 991-997.
[7]	Duan Hongfei. Diagnosis and treatment of nontuberculous mycobacteria diseases in the past 60 years [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 863-868.
[8]	Li Zhili, Liu Yuhong. Interpretation of WHO consolidated guidelines on tuberculosis. Module 6: tuberculosis and comorbidities-HIV [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 869-873.
[9]	Fu Keyan, Zhu Bangzheng, Ye Jian. Research progress on interstitial lung disease combined with Mycobacterium tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 823-829.
[10]	The Nursing Branch of Chinese Antituberculosis Association, Shanghai Pulmonary Hospital Affiliated to Tongji University Dw. Expert consensus on nursing practice for nutritional management of pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2024, 46(5): 495-501.
[11]	National Center of Medical Quality Control for Respiratory Diseases , Tuberculosis Branch of Chinese Medical Association , Tuberculosis Control Branch of Chinese Antituberculosis Association , China-Japan Friendship Hospital . Clinical practice guidelines for early detection of pulmonary tuberculosis in general medical facilities [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 127-140.
[12]	Wang Yutong, Liu Yuhong. Interpretation of World Health Organization’s Key updates to the treatment of drug-resistant tuberculosis: rapid communication [J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1303-1305.
[13]	Ming Wenhua, Ma Tingting, Wang Hongtian, Wang Xueyan. Aspirin-exacerbated respiratory diseases: pathogenesis and treatment strategies [J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1400-1405.
[14]	Daniel P. Chin, Zheng Zhijie. China can eliminate tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1185-1187.
[15]	Sha Wei. Significance and challenges of the implementation of PAN-TB treatment strategy for tuberculosis prevention and control [J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1188-1192.

Interpretation of WHO consolidated guidelines on tuberculosis Module 4: Treatment of drug-susceptible tuberculosis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 6

Related Articles 15

Recommended Articles

Metrics

Comments